Investing.com - PTC Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
PTC Therapeutics announced earnings per share of $-1.53 on revenue of $217.10. Analysts polled by Investing.com anticipated EPS of $-1.31 on revenue of $178.9M.
PTC Therapeutics shares are down 18% from the beginning of the year and are trading at $38.00 , down-from-52-week-high.
PTC Therapeutics shares lost 14.47% in after-hours trade after the report.
PTC Therapeutics follows other major Healthcare sector earnings this month
PTC Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar